Buy Urimax (Generic Flomax)

Tamsulosin is used by men to treat the symptoms of an enlarged prostate

Active substance: Tamsulosin
U.S. Brand: Flomax
Indian Brand: Urimax
Mfd by:
Strength: 0.4 mg
Form release: blister with 15 capsules
Shipping time: 7 – 21 days
Best price: 0.28 USD
through request form

DescriptionHow to take?Common Side EffectsLatest New'sPhoto's

The drug tamsulosin was first approved and used in the U.S. in 1996.

The medications marketed as Flomax and its generics are based on the active substance called Tamsulosin. It is a selective alpha-adrenergic blocker.

Generic Flomax (tamsulosin) is an alpha-blocker that relaxes the muscles in the prostate and bladder neck, making it easier to urinate. Urimax is used to improve urination in men with benign prostatic hyperplasia (enlarged prostate). Flomax is not approved for use in women or children.

Urimax capsules 0.4 mg once daily is recommended as the dose for the treatment of the signs and symptoms of BPH. It should be administered approximately one-half hour following the same meal each day. Please, note,  capsules should not be crushed, chewed or opened.

1 capsule with the dosage of the active substance 0.4 mg is taken one time a day at the same time around 30 minutes after a meal. The pill should be swallowed entirely without being crushed and washed down with sufficient amount of water.

If the standard dosage is insufficient as observed by the doctor 2 weeks after the therapy start, it can be increased to 0.8 mg a day or two pills a day taken in a single intake in the same manner as the standard dosage.
If for some reason you stop taking the pills and then want to start taking them again, regardless of what dosage you used before the therapy discontinuation, i.e. 0.4 mg or 0.8 mg, you should re-start the therapy with 0.4 mg a day and increase the dosage only after 2 weeks of uninterrupted use if the standard daily dosage is insufficient.

Urimax capsules 0.4 mg are supplied in blisters with 15 hard gelatin capsules. The capsules are imprinted on one side with Urimax 0.4 mg.

Store at 25°C (77°F); excursions permitted to 15°C–30°C (59°F–86°F) [see USP Controlled Room Temperature].

  • low blood pressure
  • nasal congestion
  • swollen ankles
  • dry mouth
  • headaches and dizziness
  • fatigue
  • problems with ejaculation

Tamsulosin for Postoperative Urinary Retention

Response from Darren J. Hein, PharmD
Assistant Professor, Department of Pharmacy Practice, School of Pharmacy and Health Professions, Creighton University, Omaha, Nebraska

Postoperative urinary retention (POUR) refers to the inability to pass any urine despite a full bladder after surgery. It is a common complaint, occurring in up to 70% of surgical patients depending on the type of surgery. Individuals undergoing perineal, gynecologic, anorectal, inguinal, and lower urinary tract surgeries are at an increased risk for POUR. Additional risk factors include older age, male sex, prolonged surgery, spinal anesthesia, and early removal of urinary catheters.

The development of POUR has been associated with several negative outcomes, including pain, urinary tract infection (UTI), bladder dysfunction, kidney damage, increased length of hospital stays, elevated costs, and the need for additional surgeries. Urethral catheterization is the mainstay of management of POUR; however, catheterization alone can also increase the risk for UTI and extend hospital stays. For these reasons, pharmacotherapeutic approaches to prevention of POUR are needed.

At least eight clinical trials evaluating the safety and effectiveness of tamsulosin, a selective alpha-1 adrenergic receptor blocker, for prevention of POUR in male patients undergoing different types of surgery have been published to date. The results of these studies have been generally consistent, with six of the eight trials reporting a statistically significant reduction in the risk for POUR with tamsulosin versus placebo. The type of surgical patient and tamsulosin regimen studied in each of the identified trials are listed in the Table below. Three observational studies also have found positive outcomes associated with the use of tamsulosin in surgical settings.

Table. Characteristics of Clinical Research Assessing Tamsulosin Therapy for Prevention of POUR

Author (Year) Tamsulosin Regimen Surgery
Jang et al (2012)[2] 0.2 mg daily from day of operation to postop day 7 Rectal cancer surgery
Mohammadi-Fallah et al (2012)[3] 0.4 mg 6 hours before and 6-12 hours after surgery Inguinal herniorrhaphy
Ahmad et al (2014)[4] 0.4 mg 6 hours before and 6-8 hours after surgery Anorectal surgery
Bazzazi et al (2014)[9] 0.4 mg daily for 1 week before surgery Cataract surgery
Jeong et al (2014)[10] 0.4 mg daily from 1 day before operation to postop day 14 Robot-assisted laparoscopic radical prostatectomy
Madani et al (2014)[5] 0.4 mg 14 hours before, 2 hours before, and 10 hours after surgery Varicocelectomy, inguinal herniorrhaphy, or scrotal surgery
Akkoc et al (2016)[6] 0.4 mg 14 hours and 2 hours before surgery Urologic surgery
Basheer et al (2017)[7] 0.4 mg 48 hours before surgery and night before surgery Spinal surgery

Tamsulosin Ineffective for Small Ureteral Stones

Medical expulsive therapy using the alpha blocker tamsulosin does not aid passage of ureteral stones less than 9 mm in diameter, according to study findings published online in JAMA Internal Medicine.

In the double-blind STONE (Study of Tamsulosin for Urolithiasis in the Emergency Department) trial, investigators randomly assigned 512 emergency department patients (mean age 41; 27% female; 23% non-white) to 0.4 mg daily tamsulosin or placebo for 28 days. Stone passage rate did not differ significantly between groups (50% tamsulosin vs 47% placebo), Andrew Meltzer, MD, of George Washington University in Washington DC, and colleagues reported. In addition, the investigators observed no significant between-group differences with respect to time to stone passage, return to work time, analgesic use, hospitalization, need for surgery, or repeat visit to the emergency department.

For the study, patients could have stones in any part of the ureter. Stone size, location, and passage were confirmed by computed tomography.

Current guidelines by the American Urological Association recommend alpha blockers for ureteral stones 10 mm or less in diameter.


Meltzer AC, Katzen Burrows P, Wolfson AB, et al. Effect of tamsulosin on passage of symptomatic ureteral stones. JAMA Intern Med. doi:10.1001/jamainternmed.2018.2259 [Published online June 18, 2018]

Dahm P and Hollingsworth JM. Medical expulsive therapy for ureteral stones—Stone Age medicine. JAMA Intern Med. [Published online June 18, 2018]

Tamsulosin Associated With Dementia Risk in Older Patients With BPH

Treatment with an α1adrenoceptor antagonist, tamsulosin, is associated with increased dementia risk among patients with symptomatic benign prostatic hyperplasia (BPH) aged ≥65 years, according to a Medicare data analysis published in Pharmacoepidemiology Drug Safety.

Using Medicare data from 2006 to 2012, investigators obtained patient data for men ≥65 years who were actively taking tamsulosin (n=253,136). These patients were compared with propensity-score-matched patients who did not use BPH medications (n=180,926), as well as patients who used doxazosin (n=28,581), terazosin (n=23,858), alfuzosin (n=17,934), dutasteride (n=34,027), and finasteride (n=38,767). Investigators used International Classification of Diseases, Ninth Revision, diagnosis codes to determine and compare incident dementia rates between each group.

A greater number of men in the tamsulosin group had dementia at the median 19.8-month follow-up compared with men who were not taking BPH medications (31.3 vs 25.9 per 1000 person-years, respectively; hazard ratio [HR], 1.17; 95% CI, 1.14-1.21; <.001). In addition, patients taking tamsulosin had a significantly higher dementia risk than those taking doxazosin (HR, 1.20; 95% CI, 1.12-1.28; P<.001), terazosin (HR, 1.11; 95% CI, 1.04-1.19; =.002), alfuzosin (HR, 1.12; 95% CI, 1.03-1.22; =.010), dutasteride (HR, 1.26; 95% CI, 1.19-1.34; <.001), and finasteride (HR, 1.13; 95% CI, 1.07-1.19; <.001).

Submit your review

Create your own review

Urimax 0.4mg
Average rating:  
 0 reviews